There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Taiwan Liposome Company Ltd (TLC) and ADMA Biologics (ADMA) with bullish sentiments.
Taiwan Liposome Company Ltd (TLC)
H.C. Wainwright analyst Oren Livnat initiated coverage with a Buy rating on Taiwan Liposome Company Ltd today and set a price target of $9. The company’s shares closed on Thursday at $5.90.
Livnat observed:
“Our $9 target is based on a probability-adjusted DCF. Our model assumes approval and launch in the U.S. of TLC599 for knee OA, self-sold by TLC. We do not include any other explicit pipeline value in our model, nor do we include any value for potential ex-US sales or royalties. We project TLC profitability in 2025 and peak sales around $500M in 2030. Our DCF uses a 12% WACC-based discount rate, and negative 10% terminal growth beyond 2030. We don’t model a cliff because TLC599 has issued IP to 2033, plus potential IP to 2039.”
According to TipRanks.com, Livnat has 0 stars on 0-5 star ranking scale with an average return of -5.8% and a 44.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Taiwan Liposome Company Ltd.
See today’s analyst top recommended stocks >>
ADMA Biologics (ADMA)
WBB Securities analyst Stephen Brozak initiated coverage with a Buy rating on ADMA Biologics today and set a price target of $9. The company’s shares closed on Friday at $4.53.
Brozak wrote:
“We believe that the ADMA Biologics, Inc. franchise is significantly undervalued. With the PDUFA dates set for BIVIGAM ® on in early 2019, we expect that both products could be major drivers of revenue in the future. Consequently, we are currently evaluating discounted cash flow models based on future FDA regulatory progress. We are assigning a $400 million replacement cost to the assets alone, which is sufficient for a 12-month target price of $9.00 per share and as such we are initiating coverage with a Speculative Buy rating.”
According to TipRanks.com, Brozak is a 4-star analyst with an average return of 12.4% and a 45.3% success rate. Brozak covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Marker Therapeutics Inc, and Kadmon Holdings.
ADMA Biologics has an analyst consensus of Strong Buy, with a price target consensus of $12.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
